Haloperidol versus placebo for schizophrenia
Información
- DOI:
- https://doi.org/10.1002/14651858.CD003082.pub2Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 18 octubre 2006see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Esquizofrenia
- Copyright:
-
- Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Claire Joy ‐ selection of trials, data extraction, writing review.
Clive Adams ‐ 10% check of trials, writing review
Steve Laurie ‐ selection of trials, 10% data extraction check, writing review
Sources of support
Internal sources
-
Cochrane Schizophrenia Group General Fund, UK.
-
University of Oxford Department of Psychiatry, UK.
External sources
-
NHS Executive Anglia and Oxford R&D Directorate, UK.
Declarations of interest
Claire Joy ‐ None.
Clive Adams ‐ has attended and presented at functions sponsored by Janssen‐Cilag and Eli Lilly. These companies have provided travel, accommodation and speaker expenses but no funds have been paid directly to CEA. Payments related to participation in meetings have been paid to an account to support schizophrenia research. The Cochrane Schizophrenia Group has multiple, and hopefully, balancing, competing interests. Potential conflicts of interest of the Group and individuals are described on http://cebmh.warne.ox.ac.uk/csg/ and sources and quantities of all funding, listed.
Steve Lawrie ‐ has been paid for speaking about critical appraisal by employees of the manufacturers of olanzapine, quetiapine, risperidone, and ziprasidone, and has been paid to speak about the management of schizophrenia by employees of the manufacturers of amisulpiride, olanzapine, risperidone, and clozapine. AM and ZN declare that they have no competing interests.
Acknowledgements
The reviewers would like to thank the funders (NHS R&D, UK) who had the vision to support this important review. Dr Jo Wood, then of Janssen‐Cilag Limited, UK, was also generous of her time and supplied a stream of rare reports of trials. We would also like to thank those who have provided editorial input to this review.
Version history
| Published | Title | Stage | Authors | Version |
| 2013 Nov 15 | Haloperidol versus placebo for schizophrenia | Review | Clive E Adams, Hanna Bergman, Claire B Irving, Stephen Lawrie | |
| 2006 Oct 18 | Haloperidol versus placebo for schizophrenia | Review | Claire B Irving, Clive E Adams, Stephen Lawrie | |
| 2001 Apr 23 | Haloperidol versus placebo for schizophrenia | Review | Claire Bronwen Joy, Clive E Adams, Stephen Lawrie | |
